Literature DB >> 25315466

Outcomes of stent-change therapy for bilateral malignancy-related ureteral obstruction.

Sang Hoon Song1, Sahyun Pak, In Gab Jeong, Kun Suk Kim, Hyung Keun Park, Choung-Soo Kim, Hanjong Ahn, Bumsik Hong.   

Abstract

OBJECTIVE: To study the long-term outcomes of stent-change therapy for malignancy-related ureteral obstruction in terms of renal function outcomes.
METHODS: We retrospectively reviewed 87 consecutive patients who underwent bilateral ureteral stenting for malignant bilateral ureteral obstruction. Predictive value of clinical variables, such as age, sex, comorbidities, renal function at time of stenting, and securing of the dominant functional kidney or both with early percutaneous nephrostomy (PCN) conversion on renal function preservation, were analyzed.
RESULTS: The mean serum Cr level was 3.3 mg/dl at the time of bilateral stenting, which significantly decreased to 1.6 mg/dl at 6 months post-stenting and progressively deteriorated to 2.3 mg/dl at 3 years post-stenting. Chronic kidney disease (CKD) stage 4 or 5 developed in 18.3% of patients at 6 months post-stenting and in 57.2% at 3 years post-stenting. During the follow-up period, 12 patients (13.8%) had PCN conversion. Patients who had early PCN conversion before progression to CKD 4 or more tended to show a better renal function outcome than patients with CKD 4 or more who had late PCN conversion or no conversion. Multivariate analysis showed that an age older than 55 years, diabetes, and an eGFR<60 before obstructive symptoms or signs were significant predictive factors for the development of CKD stage 4 or more.
CONCLUSIONS: To preserve renal function, patients with bilateral malignant ureteral obstruction, especially those aged 55 or more or with diabetes or poor baseline renal function, should be considered for early PCN conversion in the dominant functional kidney or both.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25315466     DOI: 10.1007/s11255-014-0858-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  Retrograde ureteral stents for extrinsic ureteral obstruction: nine years' experience at University of Michigan.

Authors:  Henry M Rosevear; Simon P Kim; David L Wenzler; Gary J Faerber; William W Roberts; J Stuart Wolf
Journal:  Urology       Date:  2007-11       Impact factor: 2.649

2.  Nonoperative urinary diversion for malignant ureteral obstruction.

Authors:  J A Zadra; M A Jewett; A G Keresteci; J T Rankin; E St Louis; R R Grey; J J Pereira
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

3.  Outcome of palliative urinary diversion in the treatment of advanced malignancies.

Authors:  B Shekarriz; H Shekarriz; J Upadhyay; M Banerjee; H Becker; J E Pontes; D P Wood
Journal:  Cancer       Date:  1999-02-15       Impact factor: 6.860

4.  Stent-change therapy in advanced malignancies with ureteral obstruction.

Authors:  Bradley H Rosenberg; Fernando J Bianco; David P Wood; Jeffrey A Triest
Journal:  J Endourol       Date:  2005 Jan-Feb       Impact factor: 2.942

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy.

Authors:  E Radecka; M Magnusson; A Magnusson
Journal:  Acta Radiol       Date:  2006-04       Impact factor: 1.990

7.  Palliation of obstructive nephropathy due to malignancy.

Authors:  K J Harrington; H S Pandha; S A Kelly; H E Lambert; J E Jackson; J Waxman
Journal:  Br J Urol       Date:  1995-07

8.  15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents.

Authors:  Steve Y Chung; Robert J Stein; Douglas Landsittel; Benjamin J Davies; David C Cuellar; Ronald L Hrebinko; Tatum Tarin; Timothy D Averch
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

9.  Five-year experience with metallic stents for chronic ureteral obstruction.

Authors:  Adam O Kadlec; Chandy S Ellimoottil; Kristin A Greco; Thomas M Turk
Journal:  J Urol       Date:  2013-02-26       Impact factor: 7.450

10.  Use of ileum as ureteral replacement in urological reconstruction.

Authors:  Sandra A Armatys; Matthew J Mellon; Stephen D W Beck; Michael O Koch; Richard S Foster; Richard Bihrle
Journal:  J Urol       Date:  2008-11-14       Impact factor: 7.450

View more
  5 in total

1.  Change of Renal Parenchymal Width in Patients with Unilateral Ureteral Stent: A Bicenter Retrospective Study.

Authors:  Hee Youn Kim; Seung-Ju Lee; Jin Bong Choi; Je Mo Yoo; Joon Ho Lee; Dong Sup Lee
Journal:  Biomed Res Int       Date:  2017-06-01       Impact factor: 3.411

2.  Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure.

Authors:  Mari Ohtaka; Takashi Kawahara; Daiji Takamoto; Taku Mochizuki; Yusuke Hattori; Jun-Ichi Teranishi; Kazuhide Makiyama; Yasuhide Miyoshi; Yasushi Yumura; Masahiro Yao; Hiroji Uemura
Journal:  BMC Urol       Date:  2018-05-08       Impact factor: 2.264

3.  Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction.

Authors:  Ji Hyung Yoon; Sejun Park; Sungchan Park; Kyung Hyun Moon; Sang Hyeon Cheon; Taekmin Kwon
Journal:  Investig Clin Urol       Date:  2018-10-26

4.  Bilateral ileal ureter substitution for patients with ureteral strictures secondary to gynecological tumors radiotherapy: a multi-center retrospective study.

Authors:  Xinfei Li; Weijie Zhu; Zhen Zeng; Qian Wang; Dong Fang; Zhihua Li; Hua Guan; Yanbo Huang; Peng Zhang; Hongjian Zhu; Xuesong Li; Liqun Zhou
Journal:  Transl Androl Urol       Date:  2021-08

Review 5.  Stents for malignant ureteral obstruction.

Authors:  Kristina Pavlovic; Dirk Lange; Ben H Chew
Journal:  Asian J Urol       Date:  2016-05-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.